Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05470140 | A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) | completed | Phase 1 | 9 | Allotera TherapeuticsINDUSTRY | 2 | Sep 30, 2025 | clinicaltrials |
| NCT06389357 | Retun-to-school Adaptation Program for Children With Cancer(web-based) | completed | N/A | 20 | Gazi UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05212233 | Financial Difficulty in Patients With Blood Cancer | completed | — | 218 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05238376 | Survivorship Post-HCT Optimization Program(S-POP) | completed | N/A | 16 | Duke UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06326697 | Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 32 | Hikma Pharmaceuticals LLCINDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | The Lymphoma Academic Research OrganisationOTHER | 8 | Sep 25, 2025 | clinicaltrials |
| NCT05506683 | Improving Nighttime Access to Care and Treatment; Part 2- Ghana(INACT2-G) | completed | N/A | 1,239 | University of FloridaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05509439 | Home Transfusion for HEME | completed | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05565638 | PROFAST Intervention in Precursor Multiple Myeloma(PROFAST) | completed | N/A | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04318080 | Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma(TIRHOL) | completed | Phase 2 | 46 | BeiGeneINDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT06073951 | Evaluation of a Couple-Based Physical Activity Intervention | completed | N/A | 96 | Mayo ClinicOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05471700 | Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients | completed | N/A | 40 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07188428 | Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment | completed | — | 2,298 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05223920 | An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | completed | Phase 2 | 81 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 7 | Sep 22, 2025 | clinicaltrials |
| NCT06358001 | EchoTip AcuCore Post-Market Clinical Study | completed | — | 183 | Cook Research IncorporatedINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | completed | Phase 4 | 50 | TakedaINDUSTRY | 10 | Sep 19, 2025 | clinicaltrials |
| NCT02512497 | Romidepsin Maintenance After Allogeneic Stem Cell Transplantation | completed | Phase 1 | 23 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT02858999 | Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70(LPP) | completed | Phase 2 | 40 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05442554 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma | completed | Phase 4 | 10 | TakedaINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06063603 | Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study | completed | N/A | 51 | Mayo ClinicOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07181785 | Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.(CHARTHER) | completed | — | 555 | Andrés José Maria FerreriOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT01241708 | Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma((Mel/MelVel)) | completed | Phase 3 | 148 | Hackensack Meridian HealthOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06115824 | New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen | completed | — | 136 | Huashan HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT02315768 | Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | completed | Phase 1 / Phase 2 | 32 | University of California, San DiegoOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT02631811 | Early Palliative Care in Patient With Acute Leukaemia(Pablo Hemato) | completed | N/A | 49 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04182100 | Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply | completed | Phase 2 | 29 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04385160 | Myeloproliferative Neoplasms (MPN) and COVID-19(MPN-COVID) | completed | — | 552 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 9 | Sep 15, 2025 | clinicaltrials |
| NCT05267054 | Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab | completed | Phase 1 / Phase 2 | 53 | BeiGeneINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07171827 | Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma | completed | N/A | 60 | Helwan UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT02500407 | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 713 | Genentech, Inc.INDUSTRY | 7 | Sep 12, 2025 | clinicaltrials |
| NCT04000282 | First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 37 | SanofiINDUSTRY | 6 | Sep 12, 2025 | clinicaltrials |
| NCT04045795 | Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) | completed | Phase 1 | 56 | SanofiINDUSTRY | 6 | Sep 12, 2025 | clinicaltrials |
| NCT05506956 | Post-transplant Flotetuzumab for AML | completed | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06734585 | Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant | completed | — | 114 | Astellas Pharma Singapore Pte. Ltd.INDUSTRY | 6 | Sep 12, 2025 | clinicaltrials |
| NCT04512105 | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | completed | Phase 1 | 6 | University of California, IrvineOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04018248 | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) | completed | Phase 1 | 26 | Boryung Pharmaceutical Co., LtdINDUSTRY | 2 | Sep 10, 2025 | clinicaltrials |
| NCT04862676 | Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT | completed | Early Phase 1 | 29 | University of RochesterOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03499808 | S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis | completed | Phase 2 | 43 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07162558 | The Effect of Child-centered Empowerment on Lifestyle of Leukemia Patients(lifestyle) | completed | N/A | 46 | Near East University, TurkeyOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT01916057 | Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis(CANHPARI) | completed | N/A | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT02619565 | Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes(MDS04) | completed | N/A | 349 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03078452 | Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy | completed | N/A | 100 | Emory UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04410900 | Vaccine Responsiveness After CAR-T Cell Therapy | completed | Phase 1 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06559709 | A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant | completed | N/A | 26 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06655181 | Evaluating the Effectiveness of Respiratory Muscle Training in Pediatric Kidney Transplant Patient | completed | N/A | 30 | Atlas UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04191616 | Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet(SELECT) | completed | Phase 2 | 54 | AmgenINDUSTRY | 8 | Sep 4, 2025 | clinicaltrials |
| NCT06986772 | TGRX-678 Pharmacokinetic Mass Balance | completed | Phase 1 | 6 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07155382 | Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1 | completed | — | 98 | Asan Medical CenterOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT00498043 | A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma(LNH2007-3B) | completed | Phase 2 | 222 | Hospices Civils de LyonOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT03525678 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | completed | Phase 2 | 221 | GlaxoSmithKlineINDUSTRY | 8 | Sep 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 30, 2025source: clinicaltrials